Dexcom (DC4) Stock Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DC4 Analyst Ratings

Strong Buy

21 Buy

1 Hold

1 Sell

Based on 23 analysts giving stock ratings to

Dexcom

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DC4 Stock 12 Month Forecast

Average Price Target

€77.48

▲(23.76% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Dexcom in the last 3 months. The average price target is €77.48 with a high forecast of €97.08 and a low forecast of €55.48. The average price target represents a 23.76% change from the last price of €62.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"48":"€48","73":"€73","98":"€98","60.5":"€60.5","85.5":"€85.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":97.08207712,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€97.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77.47579028666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€77.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.47547264,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€55.48</span>\n  </div></div>","useHTML":true}}],"tickPositions":[48,60.5,73,85.5,98],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.6,73.56015977846154,75.52031955692307,77.48047933538462,79.44063911384615,81.40079889230769,83.36095867076922,85.32111844923077,87.2812782276923,89.24143800615384,91.20159778461537,93.16175756307692,95.12191734153845,{"y":97.08207712,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.6,72.05198386820513,72.50396773641025,72.95595160461538,73.40793547282051,73.85991934102563,74.31190320923076,74.7638870774359,75.21587094564103,75.66785481384615,76.11983868205128,76.57182255025641,77.02380641846153,{"y":77.47579028666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.6,70.35965174153846,69.11930348307692,67.87895522461538,66.63860696615384,65.3982587076923,64.15791044923077,62.91756219076923,61.677213932307694,60.43686567384616,59.19651741538462,57.956169156923075,56.71582089846154,{"y":55.47547264,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":71.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.51,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.745,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.73,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.04,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.37,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€97.08

Average Price Target€77.48

Lowest Price Target€55.48

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Steven Lichtman

William Blair

―

Buy

―

Reiterated

07/31/26

Analyst Reiterates Buy on Dexcom, Citing Strong Q2 Growth, Expanding G7 Adoption and CMS Coverage Upside

Jayson Bedford

Raymond James

€78.88→€81.48

Buy

30.16%

Upside

Reiterated

07/31/26

DexCom price target raised to $94 from $91 at Raymond JamesDexCom price target raised to $94 from $91 at Raymond James

Jeff Johnson

Robert W. Baird

€69.34→€91.01

Buy

45.39%

Upside

Reiterated

07/31/26

DexCom price target raised to $105 from $80 at BairdDexCom price target raised to $105 from $80 at Baird

Anthony Petrone

Mizuho Securities

€78.01→€82.35

Buy

31.54%

Upside

Reiterated

07/31/26

DexCom price target raised to $95 from $90 at MizuhoDexCom price target raised to $95 from $90 at Mizuho

Richard Newitter

Truist Financial

€75.41→€80.61

Buy

28.77%

Upside

Reiterated

07/31/26

Analysts' Top Healthcare Picks: Merit Medical Systems (MMSI), Dexcom (DXCM)

Robbie Marcus

J.P. Morgan

€56.34→€71.08

Hold

13.54%

Upside

Assigned

07/31/26

DexCom price target raised to $82 from $65 at JPMorganDexCom price target raised to $82 from $65 at JPMorgan

Jonathan Block

Stifel Nicolaus

€78.01→€82.35

Buy

31.54%

Upside

Assigned

07/31/26

DexCom price target raised to $95 from $90 at StifelDexCom price target raised to $95 from $90 at Stifel

Larry Biegelsen

Wells Fargo

€73.68→€78.01

Buy

24.62%

Upside

Reiterated

07/31/26

Wells Fargo Gives a Buy Rating to Dexcom (DXCM)

Joanne Wuensch

Citi

€72.81→€76.28

Buy

21.85%

Upside

Assigned

07/31/26

DexCom price target raised to $88 from $84 at CitiDexCom price target raised to $88 from $84 at Citi

Travis Steed

Bank of America Securities

―

Buy

―

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: AptarGroup (NYSE: ATR), Mettler-Toledo (NYSE: MTD) and Dexcom (NASDAQ: DXCM)

Matthew O'Brien

Piper Sandler

€76.28→€82.35

Buy

31.54%

Upside

Reiterated

07/31/26

Dexcom (DXCM) Receives a Buy from Piper Sandler

Bruce Jackson

Benchmark Co.

€66.74→€71.08

Buy

13.54%

Upside

Reiterated

07/31/26

DexCom price target raised to $82 from $77 at BenchmarkDexCom price target raised to $82 from $77 at Benchmark

Marie Thibault

BTIG

€69.34→€78.01

Buy

24.62%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Pasithea Therapeutics Corp (NASDAQ: KTTA), Crescent Biopharma (NASDAQ: CBIO) and Dexcom (NASDAQ: DXCM)

Josh Jennings

TD Cowen

€82.35

Buy

31.54%

Upside

Reiterated

07/30/26

Dexcom: Broad-Based Revenue Beat and Margin Strength Underpin Josh Jennings’ Buy Rating

Danielle Antalffy

UBS

€83.21

Buy

32.93%

Upside

Reiterated

07/28/26

DexCom resumed with a Buy at UBSDexCom resumed with a Buy at UBS

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Steven Lichtman

William Blair

―

Buy

―

Reiterated

07/31/26

Analyst Reiterates Buy on Dexcom, Citing Strong Q2 Growth, Expanding G7 Adoption and CMS Coverage Upside

Jayson Bedford

Raymond James

€78.88→€81.48

Buy

30.16%

Upside

Reiterated

07/31/26

DexCom price target raised to $94 from $91 at Raymond JamesDexCom price target raised to $94 from $91 at Raymond James

Jeff Johnson

Robert W. Baird

€69.34→€91.01

Buy

45.39%

Upside

Reiterated

07/31/26

DexCom price target raised to $105 from $80 at BairdDexCom price target raised to $105 from $80 at Baird

Anthony Petrone

Mizuho Securities

€78.01→€82.35

Buy

31.54%

Upside

Reiterated

07/31/26

DexCom price target raised to $95 from $90 at MizuhoDexCom price target raised to $95 from $90 at Mizuho

Richard Newitter

Truist Financial

€75.41→€80.61

Buy

28.77%

Upside

Reiterated

07/31/26

Analysts' Top Healthcare Picks: Merit Medical Systems (MMSI), Dexcom (DXCM)

Robbie Marcus

J.P. Morgan

€56.34→€71.08

Hold

13.54%

Upside

Assigned

07/31/26

DexCom price target raised to $82 from $65 at JPMorganDexCom price target raised to $82 from $65 at JPMorgan

Jonathan Block

Stifel Nicolaus

€78.01→€82.35

Buy

31.54%

Upside

Assigned

07/31/26

DexCom price target raised to $95 from $90 at StifelDexCom price target raised to $95 from $90 at Stifel

Larry Biegelsen

Wells Fargo

€73.68→€78.01

Buy

24.62%

Upside

Reiterated

07/31/26

Wells Fargo Gives a Buy Rating to Dexcom (DXCM)

Joanne Wuensch

Citi

€72.81→€76.28

Buy

21.85%

Upside

Assigned

07/31/26

DexCom price target raised to $88 from $84 at CitiDexCom price target raised to $88 from $84 at Citi

Travis Steed

Bank of America Securities

―

Buy

―

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: AptarGroup (NYSE: ATR), Mettler-Toledo (NYSE: MTD) and Dexcom (NASDAQ: DXCM)

Matthew O'Brien

Piper Sandler

€76.28→€82.35

Buy

31.54%

Upside

Reiterated

07/31/26

Dexcom (DXCM) Receives a Buy from Piper Sandler

Bruce Jackson

Benchmark Co.

€66.74→€71.08

Buy

13.54%

Upside

Reiterated

07/31/26

DexCom price target raised to $82 from $77 at BenchmarkDexCom price target raised to $82 from $77 at Benchmark

Marie Thibault

BTIG

€69.34→€78.01

Buy

24.62%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Pasithea Therapeutics Corp (NASDAQ: KTTA), Crescent Biopharma (NASDAQ: CBIO) and Dexcom (NASDAQ: DXCM)

Josh Jennings

TD Cowen

€82.35

Buy

31.54%

Upside

Reiterated

07/30/26

Dexcom: Broad-Based Revenue Beat and Margin Strength Underpin Josh Jennings’ Buy Rating

Danielle Antalffy

UBS

€83.21

Buy

32.93%

Upside

Reiterated

07/28/26

DexCom resumed with a Buy at UBSDexCom resumed with a Buy at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dexcom

3 Months

Mike KratkyLeerink Partners

Success Rate

12/18 ratings generated profit

Average Return

+3.93%

Copying Mike Kratky's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.93% per trade.

1 Year

Steven LichtmanWilliam Blair

Success Rate

34/49 ratings generated profit

Average Return

+36.24%

Copying Steven Lichtman's trades and holding each position for 1 Year would result in 69.39% of your transactions generating a profit, with an average return of +36.24% per trade.

2 Years

Steven LichtmanWilliam Blair

Success Rate

37/49 ratings generated profit

Average Return

+84.11%

Copying Steven Lichtman's trades and holding each position for 2 Years would result in 75.51% of your transactions generating a profit, with an average return of +84.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DC4 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DC4 has received 34 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. DC4 average Analyst price target in the past 3 months is 77.48.

Each month's total comprises the sum of three months' worth of ratings.

DC4 Financial Forecast

DC4 Earnings Forecast

Next quarter’s earnings estimate for DC4 is €0.58 with a range of €0.54 to €0.61. The previous quarter’s EPS was €0.61. DC4 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 0.00% of the time in the same period. In the last calendar year DC4 has Performed in-line its overall industry.

DC4 Sales Forecast

Next quarter’s sales forecast for DC4 is €1.15B with a range of €1.13B to €1.17B. The previous quarter’s sales results were €1.13B. DC4 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 0.00% of the time in the same period. In the last calendar year DC4 has Performed in-line its overall industry.

DC4 Stock Forecast FAQ

What is DE:DC4’s average 12-month price target, according to analysts?

Based on analyst ratings, Dexcom’s 12-month average price target is 77.48.

What is DE:DC4’s upside potential, based on the analysts’ average price target?

Dexcom has 23.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Dexcom a Buy, Sell or Hold?

Dexcom has a consensus rating of Strong Buy, which is based on 21 buy ratings, 1 hold ratings and 1 sell ratings.

What is Dexcom’s share price target?

The average share price target for Dexcom is 77.48. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €97.08 ,and the lowest forecast is €55.48. The average share price target represents 23.76% Increase from the current price of €62.6.

What do analysts say about Dexcom?

Dexcom’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of Dexcom?

To buy shares of DE:DC4, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Dexcom (DC4) Stock Forecast & Price Target

DC4 Analyst Ratings

DC4 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dexcom

DC4 Analyst Recommendation Trends

DC4 Financial Forecast

DC4 Earnings Forecast

DC4 Sales Forecast

DC4 Stock Forecast FAQ

Detailed List of Analyst Forecasts